rs2060793 — CYP2R1

CYP2R1 rs2060793 — The Upstream Switch on Vitamin D Activation

Every unit of vitamin D you absorb from sunlight or supplements must pass through a critical gating step in the liver before it can circulate or act on your cells. The enzyme CYP2R1 (cytochrome P450 family 2 subfamily R member 1¹¹ cytochrome P450 family 2 subfamily R member 1
A microsomal enzyme encoded on chromosome 11p15.2 and expressed primarily in the liver. It performs the critical C-25 hydroxylation that converts biologically inactive vitamin D3 (cholecalciferol) into circulating 25-hydroxyvitamin D (calcidiol)) performs this conversion, and the amount of CYP2R1 enzyme your liver produces is directly influenced by the rs2060793 variant in its upstream regulatory region.

The rs2060793 SNP sits approximately 2 kilobases upstream of the CYP2R1 coding sequence. While it does not alter the enzyme's amino acid sequence, it lies within regulatory DNA that controls how strongly the gene is transcribed. Carriers of the G allele produce measurably less CYP2R1 mRNA, and therefore less 25-hydroxylase enzyme, meaning the same amount of vitamin D3 — from sunlight, food, or supplements — is converted to 25-hydroxyvitamin D (25(OH)D)²² 25-hydroxyvitamin D (25(OH)D)
The main circulating storage form of vitamin D measured on blood tests. Also called calcidiol. The normal target range is 40–80 ng/mL (100–200 nmol/L) less efficiently.

The Mechanism

The CYP2R1 upstream region containing rs2060793 is part of a haplotype block that includes several promoter-region variants influencing transcription factor binding and CYP2R1 expression levels. The G allele at rs2060793 disrupts normal regulatory element activity, reducing the transcriptional output of the CYP2R1 gene in hepatocytes. The consequence is a reduced pool of 25-hydroxylase enzyme available for vitamin D activation. This is the rate-limiting step in the vitamin D activation cascade: without adequate 25-hydroxylation in the liver, the kidney's subsequent conversion to active calcitriol (1,25(OH)₂D)³³ calcitriol (1,25(OH)₂D)
The biologically active form of vitamin D, a steroid hormone that binds the vitamin D receptor in virtually every tissue, regulating gene expression for immune function, calcium absorption, bone metabolism, and cellular differentiation is constrained by the upstream bottleneck.

Knockout mouse studies⁴⁴ Knockout mouse studies
Zhu JG et al. CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo. Proc Natl Acad Sci USA, 2013 demonstrated that eliminating CYP2R1 entirely cuts circulating 25(OH)D3 by more than 50%, establishing it as the dominant hepatic 25-hydroxylase. The rs2060793 G allele represents a partial reduction in this enzymatic capacity — less dramatic than a knockout, but additive across a lifetime of lower conversion efficiency.

The Evidence

The rs2060793 variant was first identified by Ahn et al. in 2010⁵⁵ Ahn et al. in 2010
Ahn J et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet, 2010 in a GWAS of 4,501 Europeans, reaching P=1.4×10⁻⁵ in the initial scan. A meta-analysis across studies confirmed the CYP2R1 locus at P=2.9×10⁻¹⁷, establishing it as one of the genome-wide significant determinants of circulating vitamin D alongside GC (transport protein), DHCR7/NADSYN1 (skin synthesis), and CYP24A1 (degradation).

The most mechanistically direct evidence comes from an expression study by Ekström et al.⁶⁶ expression study by Ekström et al.
Ekström L et al. Genetic Expression Profile of Vitamin D Metabolizing Enzymes in the First Trimester. Horm Metab Res, 2016 analyzing CYP2R1 mRNA levels and rs2060793 genotype. The authors found that "carriers of the G-allele of the rs2060793 SNP in the CYP2R1 gene had lower levels of CYP2R1 mRNA," with GG homozygotes showing "significantly lower CYP2R1 expression" and being "at risk for 25-hydroxyvitamin D deficiency." This expression quantitative trait locus (eQTL) effect directly demonstrates the mechanism: fewer mRNA transcripts → less enzyme protein → lower 25-hydroxylation capacity.

Cross-ethnic replication comes from Zhang et al. 2013⁷⁷ Zhang et al. 2013
Zhang Z et al. An analysis of the association between the vitamin D pathway and serum 25-hydroxyvitamin D levels in a healthy Chinese population. J Bone Miner Res, 2013, who identified the CYP2R1 haplotype AAGA (rs7936142–rs12794714–rs2060793–rs16930609) as a genetic risk factor for lower 25(OH)D in 2,897 healthy Han Chinese subjects, confirming the locus operates across diverse ancestry backgrounds.

Clinically, the variant's impact extends beyond vitamin D levels. A study of Egyptian patients⁸⁸ Egyptian patients
Sedky NK et al. Genetic Variants of CYP2R1 Are Key Regulators of Serum Vitamin D Levels and Incidence of Myocardial Infarction. Curr Pharm Biotechnol, 2018 found that rs2060793 and two other CYP2R1 variants were jointly associated with significantly lower 25(OH)D levels and increased myocardial infarction risk (OR 14.1, 95% CI 3.1–64.7 for concurrent high-risk genotypes across all three SNPs). In a cohort with polycystic ovary syndrome⁹⁹ polycystic ovary syndrome
Haldar D et al. Association of VDBP and CYP2R1 gene polymorphisms with vitamin D status in women with polycystic ovarian syndrome. Eur J Nutr, 2018, rs2060793 GA genotype was associated with increased PCOS risk specifically in women with vitamin D deficiency (p=0.05), pointing to compounded vulnerability when enzymatic conversion is impaired.

The Leiden Longevity Study¹⁰¹⁰ Leiden Longevity Study
Noordam R et al. Levels of 25-hydroxyvitamin D in familial longevity: the Leiden Longevity Study. CMAJ, 2012 added an unexpected dimension: offspring of nonagenarians (longest-lived individuals) had a significantly lower frequency of the vitamin D-raising A allele (p=0.04), paradoxically alongside lower absolute 25(OH)D levels than controls. The authors concluded this "casts doubt on the causal nature of previously reported associations between low levels of vitamin D and age-related diseases," suggesting that lower vitamin D in healthy long-lived people may reflect reduced physiologic need or confounding rather than harm.

Practical Implications

The G allele at rs2060793 acts as a throttle on the first step of vitamin D activation. Because CYP2R1 is expressed primarily in the liver, this variant affects the processing of all sources of vitamin D equally — sun-derived D3, dietary D3, and supplemental D3 are all subject to the same reduced conversion efficiency. This is important because supplementation effectively bypasses the limitation when dosed adequately: if you supplement at higher doses, you provide more substrate and more 25(OH)D is produced even with reduced enzyme levels.

The corollary is that standard-dose supplementation (600–1,000 IU) is often insufficient for G allele carriers — you may need 2–4× the typical dose to achieve the same target 25(OH)D level as an AA individual. Blood testing (serum 25(OH)D) directly measures the output of CYP2R1 and is the most reliable way to calibrate your personal dose.

Interactions

rs2060793 is in strong linkage disequilibrium with rs10741657, rs10766197, and rs16930609, all of which lie in or near the CYP2R1 regulatory region. When multiple CYP2R1 variants are present together, their effects on hepatic 25-hydroxylation are additive. Users with risk alleles at multiple CYP2R1 regulatory SNPs face a compounded reduction in D3-to-25(OH)D conversion efficiency.

Downstream pathway variants further compound the picture. GC gene variants (rs2282679, rs7041, rs4588) that reduce vitamin D binding protein (VDBP) capacity limit the amount of 25(OH)D that can be transported to the kidney for final activation. DHCR7 variants (rs12785878) that reduce skin D3 synthesis limit the substrate available for CYP2R1 to convert. A genetic risk score combining CYP2R1, GC, and DHCR7 loci can identify individuals with up to 2.47-fold increased odds of vitamin D insufficiency compared to those with no risk alleles at any of these loci.